Professor Stephen Johnston

Consultant Medical Oncologist & Professor of Breast Cancer Medicine, Royal Marsden NHS Foundation Trust, London, UK.
All views expressed are my own.

[Professor Stephen Johnston @professorSteph7]

@ESMO_Open @myESMO @stolaney1 @hoperugo @drsarahsam @JavierCortesMD @BCJoyceO Useful real world data on risk of recurrence in N1 high-risk EBC - same as TNBC at 5 years, and double the risk compared to N1 low-risk EBC.

[ESMO Open @ESMO_Open]

Exploring the treatment gap and outcome risks in patients with node+, high-risk, HR+, HER2- early BC: analyses of RW data in @ESMO_Open. Only 40% of eligible pts received adj abemaciclib. Eligible not treated: similar TNBC recurrence/mortality risk. https://t.co/GuUihbqu8y

[Paolo Tarantino @PTarantinoMD]

This is HUGE. 20 years after the approval of the latest adjuvant ET, a novel SERD may join the adjuvant arena. In the lidERA phase 3 trial, giredestrant significantly improved iDFS vs SoC ET in patients with stage I-III ER+ BC, with a positive OS trend. https://t.co/cFLCT7syxp

[CancerTherapyAdvisor @CancerTherAdvsr]

Adding abemaciclib to ET improves OS in pts with HR-positive, HER2-negative, node-positive, high-risk early breast cancer, according to results from the monarchE trial presented at #ESMO25 by @professorSteph7 of @royalmarsdenNHS. #bcsm #ESMO2025
https://t.co/295gtuC8Vc

[Susan G. Komen @SusanGKomen]

@ProfJohnCrown shared 5-year results from the NATALEE trial 🧬
Adjuvant ribociclib + aromatase inhibitors showed lasting benefit in HR+/HER2- early BC
✅ ~28% lower risk of recurrence or death
✅ Benefit seen even in node-neg (4/4)

[Susan G. Komen @SusanGKomen]

@professorsteph7 shared a 1st look at overall survival in the monarchE trial:
Abemaciclib + hormone therapy improved OS in node+ HR+/HER2- early BC
✅Risk of death reduced by15.8%
✅Metastases reduced (14% vs 20%)
✅First CDK4/6 inhibitor to show OS gain in adjuvant setting (3/4)

[PeerView @PeerView]

Don’t miss the opportunity to learn about the foundations, evidence, & practicalities of use of oral #SERDs in ER+ #MBC in this virtual #MedEd Part 1 workshop hosted by @jhaveri_komal and expert @professorSteph7 on 8/13 at 12:00 PM EDT! Produced with @MBCaware https://t.co/NTwbotfibP #BCSM

[Matteo Lambertini, MD PhD @matteolambe]

Updated data from #monarchE trial presented at #SABCS22: greater benefit with longer follow-up by adding #abemaciclib to adjuvant endocrine therapy in high-risk #BreastCancer patients…too early for assessing overall survival @SABCSSanAntonio @OncoAlert #bcsm

[Professor Stephen Johnston @professorSteph7]

@stolaney1 @OncoAlert Great to have the 4-year efficacy data from monarchE now published at https://t.co/8bo9VMguPx

[Professor Stephen Johnston @professorSteph7]

@DrMirallas @DrLisaCarey @OncBrothers @OncoAlert Great educational update session @ESMO that demonstrates the various treatment options for each subgroup of metastatic breast cancer

[Professor Stephen Johnston @professorSteph7]

Lots of new data over last year to help us with decision making in HR+ EBC - always great to debate these with colleagues attending APBCS

[APBCS 2027 @APBCSUMMIT]

Stephen Johnston @professorSteph7 walks us through practice-changing trials in the HR+ Early stage breast cancer setting at the APBCS 2022!

#apbcs2022 #breastcancer

@Shaheenah1 @RebeccaDSing

[high5md @high5md]

#monarchE: Practice changing benefit confirmed in #EBC. Don't miss Stephen R D Johnston, MD from the Royal Marsden and Nadia Harbeck, MD highlighting the facts on #high5oncologyTV. Tune in on 👉https://t.co/kBQzJ2i5G9

[FabriceAndre @FAndreMD]

The ⁦@myESMO⁩ Virtual Plenary of tomorrow is highly expected: does abema improve DFS in pts with M0 HR+ BC with longer F-up ? If benefit ⤴️ over time; how to explain the diff w trials testing palbo ? Concomitant publi in ⁦@Annals_Oncology⁩ https://t.co/PLPugjuxuL

[Justine hofland 🌈 @JustineHofland]

FDA Approves Adjuvant Abemaciclib Plus Endocrine Therapy for Select HR+ Early Breast Cancer https://t.co/lceXNxQlrA via @onclive @professorSteph7

[Professor Stephen Johnston @professorSteph7]

@JustineHofland @OncLive Fantastic news on FDA approval of adjuvant abemaciclib for those patients with high risk ER+ early breast cancer. The updated results from Monarch-E trial will be presented at the ESMO Plenary on Thursday 14th October.

[Paolo Tarantino @PTarantinoMD]

Two must-read @ASCO Guideline Updates on the treatment of HER2-negative MBC just out on JCO - featuring a stellar panel of experts

Strong endorsement for ET first in HR+ pts, single agent chemo over polychemo & wide guidance on novel biologic options

https://t.co/YpHhNpM4Kf

[The Royal Marsden Cancer Charity @royalmarsden]

We're so sorry to hear this sad news & are thinking of Helen's loved ones at this very difficult time. Helen & Damian’s support with #FeedTheNHS, a wonderful initiative established in the pandemic, supported @royalmarsdenNHS & thousands of NHS staff with free meals. Thank you🙏

[Professor Stephen Johnston @professorSteph7]

A remarkable film

[Justine hofland 🌈 @JustineHofland]

A heartbreaking watch- thinking of @kategarraway & the family. This documentary was filled with so much hope. Well done @anna_johnston & @OiWilcox for making an incredibly poignant film that summed up what the last year has been like for so many #FindingDerek

[Anna Johnston @anna_johnston]

Please tune in tonight ITV 9pm! 💛

[Professor Stephen Johnston @professorSteph7]

Great #RMBreastCancerMeeting yesterday giving update on recent research & treatment for breast cancer in the new Covid world. Thanks to RM colleagues & @trmeducation who helped organise our annual Hot Topics virtual meeting, and @RCPLondon for hosting.

[The Royal Marsden School and Conference Team @trmeducation]

Thank you so much to everyone who took part in today’s event #RMBreastCancerMeeting
Special thanks to all of our exceptional speakers, sponsors, and our amazing audience.Looking forward to see you soon again! https://t.co/SxaNDjNZU3
@RCPLondon @professorSteph7 @FionaMacNeill1